Liposomal Dry Powder Inhaler for the Treatment of Non Small Cell Lung Carcinoma NSCLC

Abstract

The death rate in lung carcinoma patients is high in overall cancer-related deaths worldwide. Non-small cell lung carcinoma (NSCLC) is the major type of lung carcinoma, about 80-85% of lung carcinoma is NSCLC. The epidermal growth factor receptor (EGFR) is newlinea transmembrane protein that mostly overexpression in NSCLC. The function of EGFR the receptor involves cell proliferation, regulating apoptosis, cell migration, and, adhesion. So, the drug that directly binds with this receptor is important to increase the survival time by reducing uneven toxicity and increasing patient compliance. Osimertinib Mesylate is a thirdgeneration newlinefirst-line reversible tyrosine kinase family of EGFR inhibitors and is considered the primary therapy of patients having NSCLC. The present work aim to develop a nanocarrier-based dry powder inhaler of Osimertinib Mesylate for the effective treatment of newlineNSCLC by the inhalation route. The present research work utilized liposomes as nanocarriers for the targeted delivery of Osimertinib Mesylate to lung cancer by the inhalation route. Osimertinib Mesylate-encapsulated liposomes were fabricated by the thin film hydration method. Formulation optimization was performed by a Response surface methodology approach. Further, Osimertinib Mesylate-loaded liposomal dispersions were converted into dry form by a validated lyophilization technique. Finally, the Osimertinib Mesylate-loaded liposomal dry powder inhaler (LDPI) was characterized. Results of the studies indicated that newlinenanocarrier systems are significantly better than the plain drug solution (conventional) newlineconcerning the targeted delivery, controlled release, higher tumor penetration capacity, and higher cytotoxic potential of an encapsulated agent. Thus, the formulated Osimertinib Mesylate-loaded PEGylated LDPI can extend the overall survival time in lung cancer patients by accurately targeting the disease location to reduce uneven side effects via the pulmonary route.